期刊文献+

高效液相色谱-串联质谱法测定动物血浆中罗匹尼罗的浓度 被引量:4

Determination of Ropinirole in Animal Plasma by LC-MS/MS
原文传递
导出
摘要 建立高效液相色谱-串联质谱(LC-MS/MS)测定动物血浆中罗匹尼罗浓度的方法。血浆经乙酸乙酯萃取后,以HPLC分离,电喷雾离子化(ESI^+)串联质谱检测。以甲醇-乙腈-0.1‰冰醋酸(36:9:55)为流动相,流速为0.2mL·min^(-1),采用Ultimate XB-C 18柱(150mm×2.1mm,3μm)分离,在三级四极杆串联质谱中经电喷雾电离源(ESI)离子化,以多反应监测(MRM)方式进行检测。盐酸罗匹尼罗、盐酸苯海拉明(内标)的扫描离子对m/Z分别为261→114和m/Z 256→167。LC-MS/MS测定血浆中罗匹尼罗线性范围为0.02—400ng·mL^(-1),范围内线性关系良好(r=0.9998);以3个浓度水平的质量控制样品求得各浓度水平日内、日间精密度(RSD)均小于15.2%。在非临床药代动力学研究中,应用此法测定了受试兔子血浆中罗匹尼罗的浓度。该法灵敏、快速、准确,操作简便,样品处理方便,线性范围宽,该方法检测快速、专一、灵敏,可满足罗匹尼罗临床前药代动力学研究和临床药动学研究的要求。 The plasma was extracted with ethyl acetate,then separated by HPLC,and detected by electrospray ionization ( ESI+ ) tandem mass spectrometry. The mobile phase of methanol-acetonitrile-0.1‰ acetic acid (36 : 9 : 55) with flow rate of 0. 2mL · min-1. The chromatographic system consisted of Ultimate XB-C18 column (150mm× 2. 1 mm, 3um). A tandem mass spectrometer equipped with electrospray ionization (ESI) source was used as detector and operated in the positive ion mode. Multiple reaction monitoring using the precursor → product ion combinations of m/Z 261 → 114 and m/Z 256→167 were used to quantify ropinirole and the internal standard, respectively. The linear calibration curve showed a good linear relationship(r=0. 9998) in the range of 0. 02--400ng · mL-1. With three concentrations of quality control samples,the obtained concentration levels of all days,the intra-and inter-day precision (RSD) were less than 15.2%. This method was used to detecte ropinirole in rabbit of pre-clinical pharmacokinetic study with sensitive and acceptable preeision, and can be used for the pre-clinical pharmacokinetie study and clinical pharmaeokinetie of ropinirole.
出处 《光谱实验室》 CAS CSCD 北大核心 2010年第6期2139-2145,共7页 Chinese Journal of Spectroscopy Laboratory
基金 国家自然科学基金资助项目(30772595)
关键词 罗匹尼罗 高效液相色谱-串联质谱法 血浆血药浓度 Ropinirole High-Performance Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Plasma Concentration
  • 相关文献

参考文献10

  • 1Clive M K, Briony N. Clinical Pharma Cokinetics of Ropinirole [J]. Drug Disposition, 2000,39 (4) : 243-254.
  • 2Stacy M,Silver D. Apomorphine for the Acute Treatement of "off" Episodes in Parkineson's Disease[J]. Pakinsonism and Related Disorders, 2008,14(2) : 85-92.
  • 3FDA批准罗匹尼罗缓释片RequipXL[J].世界临床药物,2008,29(8):449-449. 被引量:2
  • 4刘玉玲,吴浩翔.盐酸罗匹尼罗渗透泵型控释制剂及其制备方法[P].中国专利:200510081262.6,2005-12-28.
  • 5Bloomer J C,Clarke S Z,Chenzry R J. In Vitro Identtificaton of the P450 Enzymes Responsible for the Metabolism of Ropinirole [J ]. Drug Metabolism and Disposition, 1997,25(7):840-844.
  • 6Smithkline French Laboratories Limited. Ropinirole and Domperidone for Use in the Manufacture of a Medicament for the Treatment of Parkinson's Disease[P]. World's Patent: WO 92/00735 ,PCT/GB91/01121,1992-01-23.
  • 7Ramji J V,Keogh J P,Blake T J et al. Disposition of Ropinirole in Animals and Man[J]. Xenobiotica, 1999,29(3) :311-325.
  • 8文爱东,陈苏宁,杨志福,吴寅,王莉,王志睿.盐酸罗匹尼罗片的人体药动学[J].中国医院药学杂志,2007,27(6):729-731. 被引量:4
  • 9Jean H. Koller W C, Atchison M D et al. Linear Pharmacokinetic Behavior of Ropinirole Multiple Dosing in Patients with Parkinson's Divas[J]. J. Clm. Pharmacol. ,2000,40(6):641-646.
  • 10Swagzdis J E, Mico B A. Liquid Chromatographic Determination of 4 (2-di-N. N-Propylaminoethyl)-2-(3H)-Indolone in Rat, Dog, and Human Plasma with Ultraviolet Detection[J].J. Pharm. Sci. , 1986,75(1) : 90-95.

二级参考文献6

  • 1杜芳,李锐,黄远桂,乐卫东.普拉克索和罗匹尼罗对体外培养的多巴胺神经元的神经营养作用[J].中国新药与临床杂志,2004,23(8):504-509. 被引量:7
  • 2Jost WH,Angersbach D.Ropinirole,a non-ergoline dopamine agonist[J].CNS Drug Rev,2005,11 (3):253-272.
  • 3Shah VP,Midha KK,Findlay JW,et al.Bioanalytical method validation-A revisit with a decade of progress[J].Pharm Res,2000,17:1551-1557.
  • 4Deleu D,Northway MG,Hanssens Y.Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease[J].Clin Pharmacokinet,2002,41(4):261-309.
  • 5Jignesh B,Arvind J,Raghavendra S,et al.Rapid and sensitive liquid chromatography mass spectrometry method for determination of ropinirole in human plasma[J].Journal of Pharmaceutical and Biomedical Analysis,2006,40(5):1202-1208.
  • 6Kaye CM,Nicholls B.Clinical pharmacokinetics of ropinirole[J].Clin Pharmacokinet,2000,39 (4):243-254.

共引文献3

同被引文献31

  • 1文爱东,陈苏宁,杨志福,吴寅,王莉,王志睿.盐酸罗匹尼罗片的人体药动学[J].中国医院药学杂志,2007,27(6):729-731. 被引量:4
  • 2国家药典委员会.中国药典2010年版[s].二部.北京:中国医药科技出版社,2010:附录23.
  • 3NASHATIZADEH M M, LYONS K E, PAHWA R. A review of ropinirote prolonged release in Parkinson~s disease[J]. Clinical Interventions in Aging, 2009, (4): 179-186.
  • 4SHILL H A, STACY M. Update on ropinirole in the treatment of Parkinson~s disease[J]. Neu- ropsychiatric Disease and Treatment, 2009, (5): 33-36.
  • 5KULISEVSKY J, PAGONABARRAGA J. Tol- erability and safety of ropinirole versus other do- pamine agonists and levodopa in the treatment of Parkinson~s disease: Meta-analysis of random- ized controlled trials~J]. Drug Safety, 2010, 33 (2) : 147-161.
  • 6LIEBERMAN A, OLANOW CW, SETHI K, et al. A multicenter trial of ropinirole as adjunct treat- ment for Parkinson~s disease[J]. Neurology, 1998, 51(4): 1 057-1 062.
  • 7PAHWA R, STACY M A, FACTOR S A, et al. Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease[J~. Neurology, 2007, 68(14).. 1 108-1 115.
  • 8BHARATHI D V, JAGADEESH B, KUMAR S S, et al. Highly sensitive method for the deter- mination of ropinirole with a lower limit of quan- titation of 3.45 pg/mL in human plasma by LC- ESI-MS/MS: Application to a clinical pharmaco- kinetic study EJ~. Biomedical Chromatography, 2009, 23(5) : 557-562.
  • 9BHATT J, JANGID A, SHETTY R, et al. Rapid and sensitive liquid chromatography-mass spectrometry method for determination of ropini- role in human plasmaEJ~. Journal of Pharmaceu- tical and Biomedical Analysis, 2006, 40(5).. 1 202-1 208.
  • 10Food and Drug Administration. Guideline for in- dustry: Bioanalytical method validation (Draft) Es-I. 2o13.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部